- U.S. stocks declined on Tuesday, while several individual companies recorded significant share price increases driven by clinical trial results, earnings guidance updates, and funding agreements.
- Roivant Sciences shares jumped 16.3% following positive Phase 2 clinical trial data for mosliciguat, and Pharvaris gained 15.8% after releasing Phase 3 results for deucrictibant.
- IonQ raised its 2026 revenue outlook and gained 10.8% following an acquisition, while Rigetti Computing and D-Wave Quantum both secured up to $100 million in federal funding agreements.
